Pharming Group (NASDAQ:PHAR) Short Interest Update

Pharming Group (NASDAQ:PHAR) saw a significant drop in short interest in the month of June. As of June 30th, there was short interest totalling 2,900 shares, a drop of 63.8% from the June 15th total of 8,000 shares. Based on an average trading volume of 4,900 shares, the days-to-cover ratio is presently 0.6 days.

Institutional Investors Weigh In On Pharming Group

An institutional investor recently bought a new position in Pharming Group stock. Silverberg Bernstein Capital Management LLC bought a new stake in Pharming Group (NASDAQ:PHAR) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 17,710 shares of the company’s stock, valued at approximately $202,000. 0.03% of the stock is currently owned by institutional investors.

Pharming Group Stock Performance

Shares of NASDAQ:PHAR traded up $0.10 on Thursday, hitting $8.38. The company’s stock had a trading volume of 10,383 shares, compared to its average volume of 3,762. Pharming Group has a 12 month low of $6.97 and a 12 month high of $16.71. The company has a market capitalization of $563.97 million, a price-to-earnings ratio of -53.19 and a beta of 0.15. The stock’s 50-day moving average is $8.78 and its two-hundred day moving average is $10.46.

Pharming Group (NASDAQ:PHAR) last announced its earnings results on Wednesday, May 8th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.20). Pharming Group had a negative net margin of 4.01% and a negative return on equity of 4.61%. The company had revenue of $55.59 million for the quarter, compared to analysts’ expectations of $68.43 million. Equities analysts expect that Pharming Group will post -0.03 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $37.00 target price on shares of Pharming Group in a research note on Friday, May 31st.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.